pamidronate disodium

Evidence of actual tumor cell elimination, although not significant, was only obtained after preincubation of Mel-RhS with pamidronate, a phosphoantigen-inducing agent, indicating the need for additional T cell receptor-mediated signaling for Vγ9Vδ2-T cells to reach their full oncolytic potential. This study highlights the viability and persistence of Vγ9Vδ2-T cells within the 3D microenvironment, their migratory and antitumor functionality, and the suitability of the model for testing T cell-based therapies, contributing both to the understanding of Vγ9Vδ2-T cell biology and their application in cancer immunotherapy.

P4, N=240, Active, not recruiting, Ottawa Hospital Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Jun 2025

Zoledronic acid combined with chemotherapy can effectively treat bone metastases of NSCLC and improve pain stress and bone metabolic status, which has value that can be promoted and applied in clinical treatment.

The complexes studied involve four compounds: cyclosporin A (CSA), amiodarone (AMI), pamidronate (APD), and valproic acid (VPA). Furthermore, distinctive behavior was observed in the presence of active and inactive compounds, particularly in the arrangement of ATP between NBDs, supporting the proposed nucleotide sandwich dimer mechanism for ATP binding. This study provides comprehensive insights into P-gp behavior with various ligands and ATP, offering implications for drug development, toxicity assessment and demonstrating the validity of the results derived from the MD simulations.

A total of 3202 reported cases of TPLDs were associated with five BPs (alendronate, pamidronate, ibandronate, risedronate, zoledronate), with statistically significant reporting odds ratio (ROR), proportional reporting ratio (PRR), and information component (IC). The most often reported concomitant/prior medicines were calcium supplements, another BPs, antitumor agents, and nonsteroidal anti-inflammatory drugs. In conclusion, we provide a comprehensive overview of the correlation and clinical characteristics, and prognosis of BP-related TPLDs deserving continued surveillance and appropriate management.

MM treatment is coordinated by a multidisciplinary team and is dependent upon the age and physical fitness of the patient, as well as the staging of the disease. A large proportion will be treated with intravenous bisphosphonates, such as pamidronate and zoledronic acid, which places the patients at high risk for developing medication-related osteonecrosis of the jaw (MRONJ).

The hypercalcemia was treated with hyperhydration, furosemide, and pamidronate. Severe hyperparathyroidism due to parathyroid carcinoma can present as recurrent nephrolithiasis in an otherwise asymptomatic individual. Pediatric patients with a longstanding history of kidney stones should undergo screening for hypercalcemia and hyperparathyroidism even in the absence of other signs and symptoms of elevated calcium to ensure timely diagnosis and appropriate management.

Of the 48 NDMM patients presented with hypercalcemia at the time of myeloma diagnosis, 21 cases with denosumab treatment, 27 cases with bisphosphonates (3 cases of zoledronic acid and 24 cases of pamidronate acid) treatment. The incidence of treatment-induced hypocalcemia were 80.9% and 70.3% in the group with denosumab vs bisphosphonate (P > 0.05). The incidence of hypocalcemia at or over grade 3 were 19.0% and 3.7% in the group with denosumab vs bisphosphonate, respectively (P=0.106).

Patients treated with bisphosphonates included: Pamidronate and Zolendromic acid... This large-scale study based on real-world data confirms the bisphosphonates prolong survival in MM. Figure 1. Overall Survival by cohorts: In purple patients treated with bisphosphonates, in green patients without bisphosphonates (p<0.001)

Continued monthly ZOL treatment after 2 years significantly reduce the risk of progressive bone disease. 1 . Rosen, L.S., et al., Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

One year prior, she was diagnosed with mucinous adenocarcinoma of the duodenum and treated most recently with Irinotecan, the last dose being 4 days prior to this presentation, after which the patient developed significant diarrhea...Pamidronate was not recommended given her history of difficult-to-treat hypocalcemia... Hypoparathyroidism presenting later in life is usually acquired from surgical interventions, radiation to the neck or vascular injury. All these etiologies were excluded in our patient, and she was diagnosed with idiopathic hypoparathyroidism. It is postulated to be from autoimmune etiology secondary to acquired activating autoantibodies to CaSR.

Due to concern about ability to tolerate thyroidectomy, the patient was begun on selpercatinib, an oral chemotherapeutic agent specifically for tumors with disruption of RET gene...Now, 3 months out from pamidronate and her hypercalcemia has not recurred. Hypercalcemia in pediatric patients with low PTH should prompt further workup including PTHrP measurement. In this case, we report a case of a child with MEN 2A and metastasized MTC with hypercalcemia attributable to PTHrp secretion.

Patient was treated with 4 doses of calcitonin, fluids and 2 low-doses of pamidronate in the setting of AKI on CKD with only modest improvement in hypercalcemia during the hospitalization...Patient's calcium has since normalized with further treatments of denosumab, calcitonin, zoledronic acid and treatment of DLBCL with rituximab, high-dose prednisone, and cyclophosphamide with plan for surgical resection of colon adenocarcinoma.It is important to highlight that elevated 1,25-DiOH would not be typical of hypervitaminosis D as the activity of 1-alpha-hydroxylase (the enzyme that converts the inactive form of vitamin D, 25(OH)D, to the bioactive form, 1,25-DiOH) would be low with hypercalcemia...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Due to concern about ability to tolerate thyroidectomy, the patient was begun on selpercatinib, an oral chemotherapeutic agent specifically for tumors with disruption of RET gene...Now, 3 months out from pamidronate and her hypercalcemia has not recurred. Hypercalcemia in pediatric patients with low PTH should prompt further workup including PTHrP measurement. In this case, we report a case of a child with MEN 2A and metastasized MTC with hypercalcemia attributable to PTHrp secretion.

The patient received IV fluids, calcitonin, pamidronate 60 mg IV, and ergocalciferol 50,000 IU...The patient was treated with 6 cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab, as well as intrathecal methotrexate for CNS prophylaxis... ATLL-associated hypercalcemia is mediated by increased secretion of PTHrP, and RANK ligand and proinflammatory cytokines that promote RANK expression. Dmab is an effective treatment for ATLL-associated hypercalcemia as it specifically targets RANK ligand. A dose of 120 mg Dmab is recommended for patients with bisphosphonate-resistant hypercalcemia of malignancy and GFR greater than 30 mL/min.

Inpatient treatment included IV fluids, 2 doses of calcitonin and Pamidronate 60 mg IV... Atypical Parathyroid Adenomas have a clinical and biochemical profile more severe that the typical adenomas and, to some extent, similar but less severe to that of patients with parathyroid carcinoma, creating an overall diagnostic challenge. The molecular mechanisms are unclear, with germline CDC73 mutations appearing to be the most common defect. Due to uncertain malignant potential, a close and careful monitoring is recommended for these patients.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation.

She required multiple administrations of pamidronate or zoledronic acid every 4-6 weeks. We report a case where a young woman with severe symptomatic hypercalcemia was found to have primary hyperparathyroidism that was exacerbated by an underlying heterozygous mutation in CYP24A1. Our case suggests that patients with mild PTH elevation and severe hypercalcemia should be screened with 1,25-OH Vitamin D levels and 25-OH to 24,25OH Vitamin D ratio for CYP24A1 mutations. While gentle Vitamin D supplementation is often recommended in primary hyperparathyroidism, in patients with mild PTH elevations but severe hypercalcemia, CYP24A1 mutations should be considered, and Vitamin D supplements should be avoided.

P4, N=240, Recruiting, Ottawa Hospital Research Institute | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024

P2, N=80, Completed, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Oct 2022

Conclusion Present study reveals that combination of PAM and TMZ produce effective anti-cancerous effect on breast cancer cells. Therefore, this novel therapeutic regimen is likely to provide a better treatment strategy for breast cancer.

He was started on fluids for hypercalcemia and given one dose of pamidronate with a drop in corrected calcium to 10.3 mg/dL...Oncology and radiation oncology were consulted and planned to begin palliative radiation followed by chemotherapy with carboplatin and paclitaxel... Early recognition of paraneoplastic syndromes with primary tumors and guideline directed therapy can help prevent complications and other adverse outcomes from both entities.

In humanized mice, CD137 costimulation boosted the therapeutic effects of aminobisphosphonate pamidronate against EBV-induced lymphoma. Our study offers a novel approach to overcoming the obstacle of the hIL-10 and vIL-10-mediated immunosuppressive microenvironment by costimulating CD137 and enhancing the efficacy of γδ-T cell-based tumor therapy.

P2, N=80, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=60 --> 80

We find that Vγ2Vδ2 T cells express PD-1, CTLA-4, LAG-3, and TIM-3 inhibitory receptors during the 14-day ex vivo expansion period, and PD-1, LAG-3, and TIM-3 upon subsequent stimulation by pamidronate-treated tumor cells...Importantly, anti-PD-1 mAb treatment enhanced Vγ2Vδ2 T cell immunity to PC-3 tumors in immunodeficient NSG mice, reducing tumor volume nearly to zero after 5 weeks. These results demonstrate that PD-1 checkpoint blockade can enhance the effectiveness of adoptive immunotherapy with human γδ T cells in treating prostate tumors in a preclinical model.

They were given 2 courses of tetracycline labeling and then underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate...2008). This suggests that antiresorptive therapies become less effective as disease progresses.

P2, N=60, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Aug 2021 --> Dec 2021

Coexistence of 2 unrelated malignancies, whichever could be a reason for hypercalcemia of malignancy is a rare event. Severe hypercalcemia, which is possible but rare feature of CLL should be a reason for further prompt evaluation.

In conclusion, intravenous bisphosphonates may be proposed to treat persistent, moderate to severe bone pain of FD, e.g., according to the guidelines from the FD/MAS International Consortium. Oral bisphosphonates should not be used in this indication.

Unlike pamidronate-expanded cytotoxic Vδ2+ T cells, γδ Tregs lost the ability of killing AML cells...Our findings will help advance the current understanding of immune mechanism associated with leukemia cell evasion. It also proposes that boosting the cytotoxic γδ T cells should be coupled with inhibition of the suppressive γδ Tregs, for future improvement of γδ T-cell-based immunotherapy.

P2, N=60, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Aug 2021

Accordingly, pamidronate appears to affect macrophages in several ways eliciting not only its therapeutic effects but also atypical epigenetic modification, protein translation, RAS and NFkB signalings. Therefore, our observations suggest pamidronate-induced protein expressions are dynamic, and the affected proteins should be monitored by IP-HPLC to achieve the therapeutic goals during treatment.

PTPase inhibition by ARS and/or PAM treatment in both DU-145 and PC-3 cells was associated with prolonged EGFR activation. These experiments demonstrate additive or synergistic cell killing by the ARS/PAM combination in DU-145 or PC-3 cells and suggest that enhanced antitumor activity may be related to alterations in receptor tyrosine kinase signaling that occur, in part, due to ROS-mediated PTPase inhibition.

P2, N=60, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Jul 2020